Clinical Trial Update: Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and immunogenicity of a live attenuated influenza A H7N9 vaccine in healthy adults has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza Virus H7n9 Subtype Infection

Drugs mentioned

• Live Attenuated H7N9 Influenza Vaccine (Influenza A virus, H7N9 subtype live attenuated vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Influenza A Virus, H7N9 Subtype | Phase 1 | Status: COMPLETED